Hematology

The application includes new data for pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Blincyto is currently the only FDA-approved bispecific CD19-directed CD3 T cell engager immunotherapy available for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.

Nanoparticles acting as cancer drug delivery vehicles show promise in eliminating tumors.

With the increasing use of novel therapies for multiple myeloma, benchmarks are needed to assess the value of these options.

Researchers created a model framework to compare costs of 7 common regimens to treat relapsed and/or refractory multiple myeloma.

The management of individual chemotherapy regimens by pharmacists improves safety by reducing medication errors.

Early lineage T cells show promise in the treatment of acute lymphoblastic leukemia.

Proposal includes giving insurers the ability to withhold products from formularies if the cost of cancer drugs do not represent good value.

Analysts believe T-cell therapies must first show curative properties in blood cancer treatment to justify the price tag.

Analysts believe T-cell therapies must first show curative properties in blood cancer treatment to justify the cost.

Inherited genetic variations leave acute lymphoblastic leukemia patients sensitive to drugs and at risk for toxicity.

Study assessed chemotherapy use in patients with chronic myelogenous leukemia (CML) to determine how use of CML-specific tests impacted drug selection and modification.

Bone marrow stimulant helps the body make white blood cells after receiving cancer medications.

Connecticut man achieves remission via Revlimid therapy while bolstered by the love of his wife and children.

Blincyto treats adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.

Blincyto treats adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.

Novel therapeutic approach for multiple myeloma causes shows promising total cure rates.

Emend found to provide a greater delay in nausea and vomiting from cancer treatment than other medicines.

Emend found to provide a greater delay in nausea and vomiting from cancer treatment than other medicines.

Early detection is key in reducing the risk of heart failure in patients with cancer.

Empliciti is an immunostimulatory antibody that targets the Signaling Lymphocyte Activation Molecule Family member 7.

Venetoclax is an inhibitor of the B-cell lymphoma-2 protein in previously untreated AML patients.

Venetoclax is an inhibitor of the B-cell lymphoma-2 protein used in combination with hypomethylating agents in treatment-naive AML patients.

New method may offer safer alternative to target tumors and minimize awful side effects for cancer patients.

Venetoclax is a B-cell lymphoma-2 protein inhibitor for the treatment of CLL patients who received a least one prior therapy.